BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$69.48 USD
+0.35 (0.51%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $69.53 +0.05 (0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Cash flow Statements
Fiscal Year End for BioMarin Pharmaceutical Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 167.65 | 141.56 | -64.08 | 859.10 | -23.85 |
Depreciation/Amortization & Depletion | 95.16 | 105.01 | 113.19 | 105.74 | 103.30 |
Net Change from Assets/Liabilities | -336.54 | -96.38 | 66.03 | -224.42 | -101.09 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 233.00 | 25.71 | 189.39 | -655.06 | 69.90 |
Net Cash From Operating Activities | 159.26 | 175.90 | 304.54 | 85.37 | 48.26 |
Property & Equipment | -96.69 | -120.96 | -95.58 | -114.31 | -145.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -3.63 | 8.19 | -246.09 | 26.17 | 108.19 |
Other Investing Activities | -10.92 | 92.74 | -24.64 | 34.52 | 5.81 |
Net Cash from Investing Activities | -111.24 | -20.03 | -366.31 | -53.62 | -31.03 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 69.35 | 69.33 | 49.19 | 21.91 | 31.61 |
Issuance (Repayment) of Debt | -2.29 | -2.61 | -3.04 | 203.84 | -5.09 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -85.79 | -85.38 | -46.20 | -44.64 | -101.20 |
Net Cash from Financing Activities | -18.73 | -18.65 | -0.05 | 181.12 | -74.67 |
Effect of Exchange Rate Changes | 1.31 | 0.03 | -0.06 | -1.15 | 0.90 |
Net Change In Cash & Equivalents | 30.60 | 137.26 | -61.88 | 211.71 | -56.54 |
Cash at Beginning of Period | 724.53 | 587.28 | 649.16 | 437.45 | 493.98 |
Cash at End of Period | 755.13 | 724.53 | 587.28 | 649.16 | 437.45 |
Diluted Net EPS | 0.87 | 0.75 | -0.35 | 4.53 | -0.13 |
Fiscal Year End for BioMarin Pharmaceutical Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 195.84 | 88.66 | 167.65 | 147.27 | 106.89 |
Depreciation/Amortization & Depletion | 49.14 | 24.85 | 95.16 | 70.74 | 47.31 |
Net Change from Assets/Liabilities | -172.31 | -105.39 | -336.54 | -239.42 | -279.34 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 93.07 | 38.85 | 233.00 | 153.19 | 121.27 |
Net Cash From Operating Activities | 165.73 | 46.97 | 159.26 | 131.78 | -3.87 |
Property & Equipment | -37.43 | -16.10 | -96.69 | -67.77 | -46.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 122.19 | 9.87 | -3.63 | 24.63 | 47.01 |
Other Investing Activities | -8.51 | -8.00 | -10.92 | -3.14 | -1.46 |
Net Cash from Investing Activities | 76.24 | -14.24 | -111.24 | -46.28 | -0.48 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 36.62 | 7.20 | 69.35 | 54.55 | 50.19 |
Issuance (Repayment) of Debt | -0.06 | -0.04 | -2.29 | -2.24 | -1.64 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -66.74 | -49.95 | -85.79 | -81.87 | -77.34 |
Net Cash from Financing Activities | -30.18 | -42.79 | -18.73 | -29.57 | -28.78 |
Effect of Exchange Rate Changes | 5.23 | 1.93 | 1.31 | 4.96 | 2.98 |
Net Change In Cash & Equivalents | 217.02 | -8.13 | 30.60 | 60.88 | -30.15 |
Cash at Beginning of Period | 755.13 | 755.13 | 724.53 | 724.53 | 724.53 |
Cash at End of Period | 972.15 | 747.00 | 755.13 | 785.41 | 694.38 |
Diluted Net EPS | 0.55 | 0.46 | 0.10 | 0.21 | 0.29 |